Mandatory recall for Baxter pumps
This article was originally published in The Silver Sheet
FDA ordered Baxter on April 30 to recall all Colleague infusion pumps on the U.S. market and destroy the devices due to, in the agency's words, "a longstanding failure to correct many serious problems." The agency instructed Baxter to reimburse customers for the value of the pumps or provide replacements at no cost. Baxter said May 3 that initial costs of removing the roughly 200,000 pumps will run as high as $600 million. The firm plans to replace the Colleague pumps with Sigma Spectrum infusion pumps. The recall stems from a June 2006 consent decree with FDA related to the Colleague pumps. Colleague has been the subject of several recalls in the past decade for "battery swelling, inadvertent power-off, service-data errors and other issues," FDA notes in a May 3 statement. Those problems culminated in the 2006 decree that barred new sales of Colleague and Syndeo infusion pumps until the issues were resolved, but the agreement also gave FDA the authority to take further regulatory action. Baxter made numerous changes to Colleague pumps in recent years, but FDA said the company's latest series of fixes - which Baxter said would correct all known issues with the devices - was inadequate
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.